Advertisement
The number of Americans sickened with a severe lung illness tied to vaping continues to climb

Cases of Serious Vaping-Linked Lung Injury Now Top 1,000

0
New England Journal of Medicine article presents lung histopathology findings from recent cases
From 2014 to 2018

2014 to 2018 Saw Drop in Flavored Tobacco Products in Youth

0
Current use of flavored e-cigarettes among high school students increased during same period
Initiation of isoniazid preventive therapy during pregnancy is associated with increased risks versus initiation during the postpartum period

Isoniazid Tx to Prevent TB Ups Risks During HIV+ Pregnancy

0
Deferring treatment until after delivery appears to be safer option
Los Angeles County and the state of Ohio are the latest to ban flavored electronic cigarettes

Bans on Flavored Electronic Cigarettes Continue

0
Los Angeles also banning flavored tobacco products, chewing tobacco, and menthol cigarettes
The number of confirmed cases of Legionnaires' disease linked to a North Carolina state fair now stands at 79

North Carolina Legionnaires’ Case Count Climbs to 79

0
Health officials have not found cause of the outbreak
Children with asthma and with anxiety

Asthma-Related ED Use Up for Children With Anxiety, Depression

0
Children with asthma and anxiety, depression, or both have increased rates of asthma-linked ED use

September 2019 Briefing – Pulmonology

0
Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for September 2019. This roundup includes the latest...
On Monday

Juul Halts Funding for San Francisco Vaping Ballot Initiative

0
News comes as Nebraska sees first vaping-related death; U.S. total now 15
Compared with placebo

No Benefit Found for High-Dose Vitamin C Infusions in Sepsis, ARDS

0
No differences seen versus placebo in organ dysfunction scores, biomarkers of inflammation or vascular injury
For patients with progressive fibrosing interstitial lung diseases

Nintedanib Slows Fibrosing Interstitial Lung Disease

0
Nintedanib linked to lower rate of decline in forced vital capacity versus placebo in phase 3 trial